Literature DB >> 17301583

Racial disparities in the filling of warfarin prescriptions for nonvalvular atrial fibrillation.

Daniel P Schauer1, Joseph A Johnston, Charles J Moomaw, Mark Wess, Mark H Eckman.   

Abstract

BACKGROUND: Warfarin has been shown to decrease the rate of thromboembolic events in patients with nonvalvular atrial fibrillation, but it is frequently underprescribed. Our goal was to establish whether there have been racial disparities in the filling of warfarin prescriptions for patients with newly incident nonvalvular atrial fibrillation.
METHODS: We conducted a retrospective analysis of Ohio Medicaid claims between January 1, 1997 and May 31, 2002, for recipients with newly incident nonvalvular atrial fibrillation. Race was identified from the demographic information in the database, and the analysis was limited to white and African-American patients. The main outcome measure was the filling of a prescription for warfarin at any time between 7 days prior to the initial diagnosis of atrial fibrillation and 30 days after the initial diagnosis. To evaluate the independent role of race in the filling of warfarin prescriptions, we created a multivariable logistic regression model incorporating predictors significant at P < 0.10 in the univariate model.
RESULTS: A total of 6283 patients were identified as having newly incident nonvalvular atrial fibrillation, 18.5% of whom were African-American. In general, African-American patients had a higher rate of comorbid illness. Warfarin prescriptions were filled for 9.4% of white patients and 7.6% of African-American patients. When controlling for significant confounders in the multivariable logistic regression model, African-American patients had an adjusted odds ratio for receiving warfarin of 0.76 (95% CI, 0.60-0.98) when compared with white patients.
CONCLUSION: African-American patients in the Ohio Medicaid population between 1998 and 2002 were significantly less likely than white patients to fill a warfarin prescription for newly incident nonvalvular atrial fibrillation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17301583     DOI: 10.1097/00000441-200702000-00001

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  7 in total

1.  Pain in Community-Dwelling Elderly African Americans.

Authors:  Mohsen Bazargan; Hamed Yazdanshenas; David Gordon; Gail Orum
Journal:  J Aging Health       Date:  2015-06-26

2.  Risk factors of drug interaction between warfarin and nonsteroidal anti-inflammatory drugs in practical setting.

Authors:  Kyung Hee Choi; Ah Jeong Kim; In Ja Son; Kyung-Hwan Kim; Ki-Bong Kim; Hyuk Ahn; Eun Bong Lee
Journal:  J Korean Med Sci       Date:  2010-02-17       Impact factor: 2.153

3.  Initiation and persistence with warfarin therapy in atrial fibrillation according to ethnicity.

Authors:  Carolina Malta Hansen; Jonas Bjerring Olesen; Morten Lock Hansen; Aziza Azimi; Christian Torp-Pedersen; Helena Dominguez
Journal:  Front Pharmacol       Date:  2012-06-28       Impact factor: 5.810

Review 4.  Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis.

Authors:  Victoria L Baczek; Wendy T Chen; Jeffrey Kluger; Craig I Coleman
Journal:  BMC Fam Pract       Date:  2012-02-03       Impact factor: 2.497

5.  Polypharmacy among Underserved Older African American Adults.

Authors:  Mohsen Bazargan; James Smith; Masoud Movassaghi; David Martins; Hamed Yazdanshenas; Seyede Salehe Mortazavi; Gail Orum
Journal:  J Aging Res       Date:  2017-05-23

Review 6.  Use of oral anticoagulants in African-American and Caucasian patients with atrial fibrillation: is there a treatment disparity?

Authors:  Olakunle Akinboboye
Journal:  J Multidiscip Healthc       Date:  2015-05-18

7.  Polypharmacy and Psychological Distress May Be Associated in African American Adults.

Authors:  Shervin Assari; Mohsen Bazargan
Journal:  Pharmacy (Basel)       Date:  2019-01-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.